bendamustine / Generic mfg. - LARVOL DELTA

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor (ASH 2025) - P1/2, P3 | "Secondary endpoints include overall survival, PFS in patients with prior exposure to noncovalent BTK inhibitors by IRC, PFS by INV, overall response rate by IRC and INV, rate of partial response with lymphocytosis or higher by IRC and INV, duration of response by IRC and INV, time to next treatment, and safety/tolerability per National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Recruitment is ongoing."

Clinical • IO biomarker • P3 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Prolymphocytic Leukemia • Richter's Syndrome • Small Lymphocytic Lymphoma

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12) (ASH 2025) - P1/2 | "The study consists of three arms: Arm 1: Birelentinib + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6 cycles. Arm 2: Birelentinib + R-GemOx (rituximab, gemcitabine, oxaliplatin) for 8 cycles. Arm 3: Birelentinib + BR (rituximab, bendamustine) for 6 cycles...Pharmacokinetic analyses will be conducted as secondary objectives in both parts of the study. Patient enrollment for this study commenced in July 2025 and is currently ongoing."

Clinical • Combination therapy • P2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2

Safety and efficacy of ibrutinib as a first line agent for Mantle Cell Lymphoma : A systematic review and meta-analysis (ASH 2025) - "While standard first-line chemotherapy regimens include rituximab and bendamustine or cytarabine containing regimens, Bruton tyrosine kinase inhibitors (BTKis), such as ibrutinib and zanubrutinib, have demonstrated efficacy in relapsed or refractory MCL and are now being explored as frontline options. Notably, acalabrutinib in combination with bedamustine and rituximab has received FDA approval for treatment-naïve MCL patients who are ineligible for autologous hematopoietic stem cell transplantation (HSCT)...Conclusions Ibrutinib-based regimens demonstrate a high objective response rate and an acceptable safety profile when used as a first-line treatment for MCL. However, the substantial heterogeneity and potential publication bias is identified."

Retrospective data • Review • Atrial Fibrillation • Bone Marrow Transplantation • Cardiovascular • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Efficacy and safety of CAR-t cell therapy in richter transformation: A systematic review (ASH 2025) - "Lymphodepletion regimens included fludarabine/cyclophosphamide (FC) or bendamustine. CAR-T products administered were axi-cel (n=148), tisa-cel (n=131), liso-cel (n=57), brexu-cel (n=1), and investigational agents (n=29)... CAR-T therapy shows promising initial responses in RT, with ORR and CR rates comparable to de novo DLBCL. However, responses are often short-lived, with inferior PFS and OS compared to outcomes in aggressive lymphoma trials. RT patients face higher toxicity—particularly ICANS, cytopenias, and infections—reflecting disease biology and prior treatments."

CAR T-Cell Therapy • Clinical • IO biomarker • Review • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Richter's Syndrome • Thrombocytopenia • IGH • TP53

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status (ASH 2025) - "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) is a common regimen that is well-tolerated in older adults with other comorbidities, for whom treatment of DLBCL is challenging and has inferior outcomes...The most common 2L treatment regimens were rituximab, ifosfamide, carboplatin, plus etoposide in ASCT (n=41, 62.1%) and bendamustine plus rituximab (n=62, 18.6%) in non-ASCT treated groups...A higher percentage of patients in the non-ASCT treated group, specifically in the R-GemOx subgroup, were older with higher ECOG scores and inferior treatment related outcomes, including a minority alive at 2 years. These findings highlight a continuing unmet need for more effective, safer treatments for patients with R/R DLBCL ineligible for or unable to access ASCT or CAR-T."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience (ASH 2025) - "Twenty-two patients (73.3%) received R-CHOP as first-line chemoimmunotherapy...Two patients (6.7%) had prior anti-CD19 therapy, five (16.7%) had bendamustine exposure, and all patients received prior anti-CD20 monoclonal antibody...The most commonly used CART product was axicabtagene ciloleucel (N=28, 93%)...Tocilizumab was administered in 19 patients (63.3%), with 13 (68.4%) requiring only one dose...All ICANS patients received steroids, and four (33.3%) received anakinra...These findings affirm the safety and efficacy of autologous CD19-directed CAR T-cell therapy in routine clinical practice at a medium-sized academic institution. Continued research with larger sample sizes and extended follow-up periods is warranted to validate these results further."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States (ASH 2025) - "Treatment regimens were categorized into 7 mutually exclusive groups: bendamustine (B)-based chemotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without cytarabine), Bruton tyrosine kinase inhibitors (BTKi; covalent: zanubrutinib, acalabrutinib, ibrutinib, and non-covalent: pirtobrutinib), bortezomib (bort)-based, venetoclax (ven)-based, intensive chemotherapy (high-dose cytarabine, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, etc.), and other regimens (CAR-T or others). However, chemotherapy and/or immunotherapy were associated with the highest HCRU while BTKi were associated with the lowest HCRU. Notably, more than half of patients previously treated with BTKi and anti-CD20 therapies were subsequently treated with another covalent BTKi or a non-covalent BTKi, while approximately one-third received chemotherapy and/or immunotherapy, further emphasizing the need for novel..."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors (ASH 2025) - "All 4 DLBCL patients received R-CHOP or R-CHOP-like regimens as 1L therapy, while the MCL patient received bendamustine and rituximab (BR) as 1L therapy. Consolidation therapy with CAR-T following 1L treatment demonstrated encouraging rates of CMR, PFS, and OS in B-cell lymphoma patients with high risk of relapse. Administration of PD-1 inhibitors and/or IL-2 post-infusion may support sustained expansion and persistence of CAR-T cells. The safety profile was manageable: all CRS were mild, and no ICANS were observed, providing a valuable insight for CAR-T consolidation following 1L treatment."

Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatology • Large B Cell Lymphoma • Leukopenia • Liver Failure • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Thrombocytopenia • IL2

A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada (ASH 2025) - "For younger, fit patients with favourable-risk genetic markers such as the absence of del(17p)/ TP53 mutations and mutated IGHV, first-line (1L) chemoimmunotherapy (CIT) with fludarabine, cyclophosphamide, and rituximab (FCR) remains a reasonable option. With the emergence of targeted fixed-duration (FD) therapies, such as venetoclax plus obinutuzumab (V+O) and ibrutinib plus venetoclax (I+V), which have demonstrated superior efficacy and reduced toxicity, CIT use has declined in the 1L setting (Al-Sawaf et al., 2024; Schnaiter et al., 2024; George et al., 2025)...Among patients receiving CIT, 61 (30.5%) received FCR, 76 (38%) received bendamustine plus rituximab (BR), 26 (13%) received chlorambucil plus obinutuzumab (Clb+O), and 6 (3%) received chlorambucil plus rituximab (Clb+R)... In this chart-reviewed cohort of 200 patients, the average age at diagnosis was 65 years and 69.8% were male. 22% and 22.5% presented with Rai stage 3 or 4, respectively, at 1L therapy..."

Clinical • Genomic analysis • IO biomarker • Omic analysis • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • IGH • TP53

Physicians perceptions of fixed-duration epcoritamab + lenalidomide and rituximab regimens in relapsed/refractory follicular lymphoma: Insights from the epcore NHL-2 trial (ASH 2025) - "Before reviewing trial data, despite 40% reporting BsAb use, only 29% reported they would select BsAbs (i.e., mosunetuzumab, epcoritamab) as their preferred 3L regimen for a hypothetical patient with R/R FL (65-year-old male, stage III, and an ECOG PS of 1 who received R-CHOP in 1L and bendamustine + rituximab in 2L), and most respondents preferred CAR T therapy (42%) for this patient. U.S. oncologists demonstrated increased interest in the fixed duration of ER2 following review of EPCORE NHL-2 data, with a notable shift in preference from CAR T to BsAbs in earlier lines of treatment for R/R FL. The regimen's defined treatment duration and potential for use in 2L settings were key drivers of interest. These findings suggest that ER2 may offer a clinically attractive alternative to existing therapies, particularly for patients' ineligible for CAR T or those seeking outpatient, time-limited options."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Use of bispecific antibody talquetamab before leukapheresis may lead to out-of-specification ciltacabtagene autoleucel manufacturing: A university of Arizona experience (ASH 2025) - "One IS patient received prior bendamustine; none in the OOS group did. Exposure to bispecific T-cell engager therapy was significantly more common in the OOS group (4/5 vs. 1/10; p = 0.016), with all OOS exposures involving talquetamab and the IS exposure involving teclistamab... In this single-institution cohort, patients who received OOS cilta-cel products experienced safety and efficacy outcomes comparable to those treated with IS products. These findings support the potential utility of selected OOS CAR T-cell products under appropriate oversight. Exposure to talquetamab prior to leukapheresis was significantly associated with OOS product status."

Hematological Malignancies • Infectious Disease • Influenza • Multiple Myeloma • Respiratory Diseases

Comparative efficacy and safety of bendamustine versus fludarabine and cyclophosphamide as lymphodepleting regimens for CAR-T therapy in hematological malignancies: A systematic review and meta-analysis (ASH 2025) - "Axicabtagene ciloleucel was used in four studies, brexucabtagene autoleucel and tisagenlecleucel in two studies, and lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel in one study each. These findings suggest that bendamustine may serve as a viable alternative LD regimen, especially for patients at high risk of infections. Further prospective studies are warranted to confirm the safety and efficacy of bendamustine compared to standard FluCy regimen."

Retrospective data • Review • Acute Lymphocytic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis (ASH 2025) - "The DK-based regimens (DKd; DKBd; DKCd; DKRd) — combining daratumumab, carfilzomib, dexamethasone ± bendamustine, cyclophosphamide, or lenalidomide — were administered in 28-day cycles (≥2 cycles). DK-based regimens achieved high effectivity in patients with NDMM not undergoing ASCT, including those with EMD. Efficacy improved with prolonged treatment. The combination of carfilzomib and daratuzumab aligns with published data, confirming feasibility and effectiveness."

Retrospective data • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Multiple Myeloma • Neutropenia • Pulmonary Disease

Successful melphalan flufenamide (melflufen) therapy in patients with severe renal insufficiency (ASH 2025) - "Before melflufen, the patient received 5 prior therapies all of which were discontinued due to different reasons: VMP (10 mo) – progredient disease (PD), Rd (3 mo) – drug exanthema, Vd (7 mo) - PD, DaraKd (10 mo) – heart insufficiency, and DaraPd (4 mo) which was adjusted to daratumumab monotherapy due to side effects on pomalidomide...In total, 9 different prior therapies were administered and discontinued before the use of melflufen: thalidomide/doxorubicine/dexamethasone (12 mo) with thalidomide as a maintenance therapy (2 y) – PD, Vd (12 mo) – polyneuropathy, bendamustine/prednisolone (5 mo) - PD, KRd (4 mo) – VGPR, discontinuation due to patient's request, EloRd (9 mo) – VGPR, DaraRd (2 y) and daratumumab monotherapy (4 mo) - PD, IsaPomd (5 mo) – PD, and liposomal doxorubicine/bortezomib (2 mo)... Both clinical cases showed that melphalan flufenamide (melflufen) can be administered in a reduced dose of e.g. 20 mg and is a highly effective and well-tolerated..."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Malignancies • Infectious Disease • Metabolic Disorders • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Orthopedics • Pulmonary Arterial Hypertension • Renal Disease • Type 2 Diabetes Mellitus • B2M

CD5-positive lymphoproliferative disorders with atypical phenotypes are associated with inferior overall survival compared to typical-phenotype chronic lymphocytic leukaemia when treated with targeted agents. (ASH 2025) - "Chemotherapy (CT) or chemoimmunotherapy (CIT) was the first line treatment in 15 (58%) and targeted treatment (TT) in 11 (42%) including bendamustine + rituximab in 6 (23%), fludarabine + cyclophosphamide + rituximab in 3 (11.5%), dexamethasone+ cyclophosphamide+ rituximab in 2 (7.7%), chlorambucil in 3 (11.5%), rituximab alone in 1 (3.8%), acalabrutinib in 6 (23%), ibrutinib in 2 (7.7%), Zanubrutinib + venetoclax (clinical trial) in1 (3.8%) and venetoclax + obinutuzumab in 2 (7.7%). Massive splenomegaly is a major feature in patients with CD5+LPD with atypical phenotype. These patients have an inferior OS outcome when treated with TT compared to CLL patients with typical phenotype."

Clinical • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • CCND1 • CD5

Evaluation of response assessment in chronic lymphocytic leukaemia using measurable residual disease by flow cytometry: Prospective observational study. (ASH 2025) - "Treatments included Acalabrutinib (37.9 %), Bendamustine plus Rituximab (34.5%), Ibrutinib plus Rituximab (17.2%), and single cases of Venetoclax plus Rituximab, R-CHOP, and Mini R-CHOP plus Acalabrutinib. The study is limited by a small sample size for statistical analysis and a shorter follow-up period. Overcoming these limitations would give an answer for the accurate estimation of response to therapy in CLL for future response-guided therapy."

Clinical • IO biomarker • Observational data • Residual disease • Aplastic Anemia • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Richter's Syndrome • Thrombocytopenia • IGH • NOTCH1 • TP53

A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL) (ASH 2025) - P2, P3 | "The phase 3 SEQUOIA trial (NCT03336333) evaluated zanubrutinib in treatment-naive (TN) patients without del(17p) mutations (arm A), in comparison with bendamustine + rituximab in the same population (arm B), and as monotherapy in patients with del(17p) mutations (arm C). With the longest available follow-up, zanubrutinib demonstrated a statistically significant PFS benefit over V+I in the GLOW population. In the comparison of CAPTIVATE vs SEQUOIA, a trend favoring zanubrutinib was observed, though statistical significance was not reached due to limited ESS caused by substantial baseline heterogeneity. These findings reinforce the robustness of the efficacy of zanubrutinib in TN patients with CLL and suggest improved outcomes compared with fixed-duration V+I across diverse patient populations."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • B2M • TP53

Discovering the epidemiology, treatment patterns, and outcomes of chronic lymphocytic leukemia: A retrospective multicenter cohort study (ASH 2025) - "Among patients who required treatment, the most commonly used regimens were FCR (22.2%), R-CHOP (20%), R-COP (18%), R Bendamustine (15%), Obinutuzumab Venetoclax (12%), and BTK inhibitors (10%). We believe that this limitation does not allow patients to be treated according to their risks, which is why we see a high percentage of patients still receiving immunochemotherapy, which is not in accordance with international guidelines. Knowing these data allows us to increase efforts to improve access to diagnosis and targeted treatments in our country."

Retrospective data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

A Phase II study of time-limited treatment with orelabrutinib plus bendamustine and obinutuzumab (OBG) in patients with treatment-Naïve CLL/SLL patients (ASH 2025) - "Background: FCR (fludarabine, cyclophosphamide, and rituximab) has been demonstrated to improve outcomes in previously untreated Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) CLL patients, but only for suitable patients, which limits it clinical application.Lower toxicity strategies, such as Bendamustine-Obinutuzumab or Bendamustine-Rituximab, demonstrated better tolerability but did not achieve comparable efficacy.BTK inhibitors (BTKi) are recommended for long-term therapy in CLL/SLL and time-limited treatment regimen has been hot topics. The Time-Limited Treatment of OBG regimen shows efficacy in unfit CLL/SLL patients, which achieved high rates of complete response combined with undetectable minimal residual disease. Safety analysis indicates that the OBG regimen is well-tolerated and adverse events are manageable. These findings support further investigation of the OBG regimen to optimize treatment outcomes in this patient population."

Clinical • P2 data • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Hypertension • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma • Thrombocytopenia • Varicella Zoster • IGH • TP53

The clinical trials landscape in chronic lymphocytic leukemia: A systematic review of control arm adequacy (ASH 2025) - "The Alliance A041202 and CLL14 trials demonstrated substantial progression-free survival (PFS) benefits of BTKi monotherapy and fixed-duration venetoclax plus obinutuzumab (Ven/Obi), respectively, establishing them as standard first-line treatments...Six trials (42.8%) employed substandard control arms, all utilizing a combination of chemoimmunotherapy: fludarabine/cytarabine/rituximab or bendamustine/rituximab (n=4) or chlorambucil and rituximab (n=2)...Notably, 2 of the BTKi trials utilized ibrutinib rather than next-generation BTKis, such as acalabrutinib or zanubrutinib... Of all modern phase III trials for treatment-naive CLL, nearly half did not utilize control arms that align with the current SOC in the US or EU, risking inflated estimates of the efficacy of their experimental therapies and compromising the external validity of their results. However, although the small sample size limited statistical analysis, we found that the majority of these trials were..."

Clinical • Review • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials (ASH 2025) - "Comparisons were drawn between ven-based regimens including doublets [Ven+Obinutuzumab (Obi), Ven+Ibrutinib (Ibr), Ven+Acalabrutinib (Acala)] and triplets (BTKi + Ven + Obi) and CIT comparators such as chlorambucil+Obi or fludarabine (Flu)-based combinations...Flu cyclophosphamide rituximab/bendamustine rituximab N=519, ORR, PFS 1 year, and PFS 2 years were given as 88% (CI 56-98%), 91% ( CI 86-94%), and 80% (CI 77-84%), respectively... Ven+Obi consistently showed superior PFS and ORR compared to CIT, positioning it as a frontline standard for time-limited therapy. While the Ven+Ibr combination offered similar durability, it introduced higher cardiovascular toxicity, requiring patient-specific consideration. The addition of a third agent did not yield meaningful clinical benefit in PFS but increased myelosuppression, underscoring the need for regimen personalization."

Retrospective data • Review • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Neutropenia

First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry (ASH 2025) - "Randomized trials such as CLL14 and CLL13 have demonstrated the superiority of venetoclax-obinutuzumab (VenO) over chemoimmunotherapy in both elderly and younger, fit patients...Three-year TTNT rates were: R-chlorambucil 34%, G-chlorambucil 51%, R-bendamustine 78%, FCR 67%, VenR 77%, and VenG 83%... Real-world data from this cohort allowed us to compare venetoclax-based regimens with CIT as first-line therapy for CLL, including high-risk patients. As expected, venetoclax-based regimens showed favorable results, and their use should be considered as an effective time-limited therapy, even in lower-middle-income countries. Updated analyses with longer follow-up and broader inclusion will be presented at the meeting."

Clinical • IO biomarker • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • B2M • TP53

Systemic mastocytosis with associated lymphoid neoplasms (SM-ALN): A distinct subset with indolent clinical course and favorable outcomes (ASH 2025) - "SM management was divided into two categories: (1) Conservative approach, including observation alone in 4 patients (22%) and symptomatic therapies such as antihistamines or leukotriene inhibitors in 7 (39%); and (2) Cytoreductive treatments, comprising avapritinib in 5 patients (28%), cladribine in 1 (6%), and imatinib in 1 (6%). Management of lymphoid neoplasms included intensive regimens such as R-CHOP and hyper-CVAD for high-grade subtypes (e.g., DLBCL and T-ALL), while indolent forms (e.g., CLL and follicular lymphoma) were treated with bendamustine-rituximab or observation depending on disease burden... SM-ALN is a rare but distinct SM subtype characterized by indolent behavior, favorable treatment responses, and prolonged survival. Recognition of this subset is critical to avoid over-treatment and to guide risk-adapted management strategies."

Clinical • Acute Lymphocytic Leukemia • Aggressive Systemic Mastocytosis • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Dermatology • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Pruritus • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • ASXL1 • CCND3 • CXCR4 • DNMT3A • IDH1 • JAK2 • KIT • MYD88 • NOTCH2 • RUNX1 • SF3B1 • SRSF2 • TET2 • TP53

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma (ASH 2025) - "Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) following at least one prior line of therapy, either as monotherapy or in combination with gemcitabine and oxaliplatin (GemOx)...Specifically, 6 patients (17.1%) had a history of bendamustine exposure, and 4 patients (11.4%) had undergone both autologous stem cell transplantation and chimeric antigen receptor T-cell therapy...Among them, the regimens included glofitamab monotherapy (28, 80.0%), glofitamab combination with bruton tyrosine kinase inhibitors (3, 8.6%), GemOx (2, 5.7%), polatuzumab vedotin (1, 2.9%) or dose-reduced ifosfamide, carboplatin and etoposide (1, 2.9%)... Our findings characterize disease features of heavily treated r/r aggressive B-cell lymphoma and real-world outcomes with glofitamab-based salvage. Even in the subgroups with adverse prognosis factors, glofitamab-based regimens still demonstrated..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD4 • TP53